2nd Quarter - Termination

HOWARD CONSULTING GROUP, INC. for PARATEK PHARMACEUTICALS

Period 2nd Quarter 2019 Filed Jul 25, 2019 Signed by Frank Howard, Jr.

Official filing
Firm
HOWARD CONSULTING GROUP, INC.
Client
PARATEK PHARMACEUTICALS
Income
$15,500
Expenses
—
Terminated
Jun 30, 2019

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

- Funding of antimicrobial research, development and investments - Strategic National Stockpile(s) (CDC, DoD, DHS) - Drug rebates

LobbyistCovered position, as disclosed
FRANK HOWARD —

Contacted: Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); SENATE

Defense DEF

- Funding of antimicrobial research, development and investments - Strategic National Stockpile(s) (CDC, DoD, DHS) - Drug rebates - Research funding from MCS & DoD

LobbyistCovered position, as disclosed
FRANK HOWARD —

Contacted: Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES

Homeland Security HOM

- antimicrobial stockpiles

LobbyistCovered position, as disclosed
FRANK HOWARD —

Contacted: Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.